{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T13:43:22Z","timestamp":1773409402024,"version":"3.50.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.3816\/clm.2009.s.022","type":"journal-article","created":{"date-parts":[[2009,9,29]],"date-time":"2009-09-29T10:04:58Z","timestamp":1254218698000},"page":"S266-S271","source":"Crossref","is-referenced-by-count":7,"special_numbering":"S3","title":["Measuring Minimal Residual Disease in Chronic Myeloid Leukemia: Fluorescence In Situ Hybridization and Polymerase Chain Reaction"],"prefix":"10.3816","volume":"9","author":[{"given":"Timothy P.","family":"Hughes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Branford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2009.s.022_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1535-6108(02)00025-9","article-title":"Perspectives on the development of a molecularly targeted agent","volume":"1","author":"Druker","year":"2002","journal-title":"Cancer Cell"},{"key":"10.3816\/CLM.2009.s.022_bib2","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1182\/blood-2004-02-0711","article-title":"Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-{alpha}","volume":"104","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.022_bib3","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.022_bib4","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/sj.leu.2403426","article-title":"Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance","volume":"18","author":"Hochhaus","year":"2004","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.s.022_bib5","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.hoc.2004.03.001","article-title":"Clinical resistance to imatinib: mechanisms and implications","volume":"18","author":"Hochhaus","year":"2004","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.3816\/CLM.2009.s.022_bib6","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.022_bib7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.blre.2005.01.008","article-title":"Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia","volume":"20","author":"Hughes","year":"2006","journal-title":"Blood Rev"},{"key":"10.3816\/CLM.2009.s.022_bib8","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1365-2141.1999.01749.x","article-title":"Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics","volume":"107","author":"Branford","year":"1999","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.s.022_bib9","first-page":"49","article-title":"Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy","volume":"89","author":"Lange","year":"2004","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2009.s.022_bib10","first-page":"160","article-title":"Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia","volume":"9","author":"Kantarjian","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2009.s.022_bib11","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.022_bib12","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/nature03669","article-title":"Dynamics of chronic myeloid leukaemia","volume":"435","author":"Michor","year":"2005","journal-title":"Nature"},{"key":"10.3816\/CLM.2009.s.022_bib13","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1182\/blood-2004-03-1134","article-title":"Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations","volume":"104","author":"Branford","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.022_bib14","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1158\/1078-0432.CCR-07-1112","article-title":"A half-log increase in BCR-ABL RNA Predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response","volume":"13","author":"Press","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2009.s.022_bib15","first-page":"235","article-title":"The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinibtreated patients with chronic myeloid leukemia","volume":"91","author":"Wang","year":"2006","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2009.s.022_bib16","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/sj.leu.2404139","article-title":"Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL","volume":"20","author":"Ross","year":"2006","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.s.022_bib17","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1600-0609.2004.00287.x","article-title":"Assessment of the response to imatinib in chronic myeloid leukemia patients\u2013comparison between the FISH, multiplex and RT-PCR methods","volume":"73","author":"Raanani","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLM.2009.s.022_bib18","first-page":"994","article-title":"Fluorescence in situ hybridization analysis of minimal residual disease and the relevance of the der(9) deletion in imatinib-treated patients with chronic myeloid leukemia","volume":"91","author":"Calabrese","year":"2006","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2009.s.022_bib19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.leu.2402329","article-title":"Comparison of chromosome banding analysis, interphase-and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases","volume":"16","author":"Schoch","year":"2002","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.s.022_bib20","first-page":"295","article-title":"Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ Chronic Myeloid Leukemia patients treated with imatinib mesylate","volume":"23","author":"Fugazza","year":"2004","journal-title":"J Exp Clin Cancer Res"},{"key":"10.3816\/CLM.2009.s.022_bib21","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/sj.leu.2403077","article-title":"FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib","volume":"17","author":"Reinhold","year":"2003","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.s.022_bib22","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1182\/blood.V92.7.2315","article-title":"A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia","volume":"92","author":"Buno","year":"1998","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.022_bib23","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1182\/blood.V95.3.738.003k21_738_743","article-title":"Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia","volume":"95","author":"Sinclair","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.022_bib24","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1182\/blood.V98.6.1732","article-title":"Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia","volume":"98","author":"Huntly","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.022_bib25","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/gcc.10197","article-title":"A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression","volume":"37","author":"Lee","year":"2003","journal-title":"Genes Chromosomes Cancer"},{"key":"10.3816\/CLM.2009.s.022_bib26","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/cncr.23607","article-title":"No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR\/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia","volume":"113","author":"Kim","year":"2008","journal-title":"Cancer"},{"key":"10.3816\/CLM.2009.s.022_bib27","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.022_bib28","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.163.163","article-title":"Continuing reduction in level of residual disease after 4 years in patients with CML in chronic phase responding to first-line imatinib (IM) in the IRIS study","volume":"106","author":"Goldman","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.022_bib29","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","article-title":"High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia","volume":"103","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.022_bib30","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1182\/blood-2005-11-4406","article-title":"BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML","volume":"107","author":"Press","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.022_bib31","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1158\/1078-0432.CCR-05-2574","article-title":"Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients","volume":"12","author":"Iacobucci","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2009.s.022_bib32","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.164.164","article-title":"Maintenance of imatinib dose intensity in the first six months of therapy for newly diagnosed patients with CML is predictive of molecular response, independent of the ability to increase dose at a later point","volume":"106","author":"Hughes","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.022_bib33","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/sj.leu.2404388","article-title":"Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia","volume":"20","author":"Branford","year":"2006","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.s.022_bib34","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","article-title":"High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance","volume":"99","author":"Branford","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.022_bib35","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.022_bib36","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2009.s.022_bib37","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/sj.leu.2404236","article-title":"Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(varphi)-LMC GROUP)","volume":"20","author":"Nicolini","year":"2006","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.s.022_bib38","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood-2005-03-1036","article-title":"High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy","volume":"106","author":"Willis","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.022_bib39","first-page":"69","article-title":"Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCR","volume":"Vol 125","author":"Branford","year":"2006"},{"key":"10.3816\/CLM.2009.s.022_bib40","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1200\/JCO.2005.05.531","volume":"23","author":"Soverini","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.022_bib41","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"issue":"s1","key":"10.3816\/CLM.2009.s.022_bib42","first-page":"206","article-title":"Within the P-loop group, the Y253H and E255K\/V ABL kinase domain mutations are of particular severe prognosis in chronic myelogenous leukemia patients resistant to imatinib mesylate","volume":"92","author":"Nicolini","year":"2007","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2009.s.022_bib43","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1128\/MCB.02202-05","article-title":"Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib","volume":"26","author":"Griswold","year":"2006","journal-title":"Mol Cell Biol"},{"key":"10.3816\/CLM.2009.s.022_bib44","doi-asserted-by":"crossref","first-page":"19466","DOI":"10.1073\/pnas.0609239103","article-title":"Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants","volume":"103","author":"Skaggs","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.3816\/CLM.2009.s.022_bib45","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1038\/sj.onc.1210302","article-title":"TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes","volume":"26","author":"Petitjean","year":"2007","journal-title":"Oncogene"},{"key":"10.3816\/CLM.2009.s.022_bib46","doi-asserted-by":"crossref","first-page":"101a","DOI":"10.1182\/blood.V110.11.322.322","article-title":"Philadelphia chromosome-positive leukemia patients who harbor imatinib-resistant mutations have a higher likelihood of developing additional mutations associated with resistance to novel tyrosine kinase inhibitors","volume":"110","author":"Soverini","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.022_bib47","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.022_bib48","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.leukres.2007.03.031","article-title":"International standardisation of quantitative real-time RT-PCR for BCR-ABL","volume":"32","author":"Cross","year":"2008","journal-title":"Leuk Res"},{"key":"10.3816\/CLM.2009.s.022_bib49","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.1158\/1078-0432.CCR-07-0844","volume":"13","author":"Branford","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2009.s.022_bib50","first-page":"162","article-title":"Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment","volume":"91","author":"Colombat","year":"2006","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2009.s.022_bib51","first-page":"155","article-title":"Pitfalls of quantitative real-time reverse-transcription polymerase chain reaction","volume":"15","author":"Bustin","year":"2004","journal-title":"J Biomol Tech"},{"key":"10.3816\/CLM.2009.s.022_bib52","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia -a Europe Against Cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.s.022_bib53","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/leu.2008.330","article-title":"Reply to \u2018What do we mean by sensitivity when we talk about detecting minimal residual disease?\u2019 by Steinbach and Debatin","volume":"23","author":"Ross","year":"2009","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.s.022_bib54","doi-asserted-by":"crossref","DOI":"10.1373\/clinchem.2008.105916","article-title":"Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: implications for defining sensitivity in minimal residual disease","author":"Ross","year":"2008","journal-title":"Clin Chem"},{"key":"10.3816\/CLM.2009.s.022_bib55","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155791901170350X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155791901170350X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T15:47:12Z","timestamp":1590162432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155791901170350X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":55,"alternative-id":["S155791901170350X"],"URL":"https:\/\/doi.org\/10.3816\/clm.2009.s.022","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}